Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

5(55.6%)

Phase 3

2(22.2%)

Phase 1

2(22.2%)

9Total

Phase 2(5)

Phase 3(2)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07104383Phase 3Recruiting

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

Role: lead

NCT02578095Phase 2Completed

Acute Hip Fracture Study in Patients 65 Years or Greater

Role: lead

NCT07104500Phase 3Active Not Recruiting

VK2735 for Weight Management Phase 3

Role: lead

NCT06828055Phase 2Completed

VK2735 for Weight Management Phase 2 (Venture Oral Dosing)

Role: lead

NCT04973657Phase 1Completed

A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN

Role: lead

NCT05203237Phase 1Completed

Phase 1 Study to Evaluate the Safety and Tolerability of VK2735

Role: lead

NCT06068946Phase 2Completed

VK2735 for Weight Management Phase 2

Role: lead

NCT04173065Phase 2Completed

A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH

Role: lead

NCT02927184Phase 2Completed

Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease

Role: lead

All 9 trials loaded